According to 2019 China In Vitro Diagnosis Industry Report, which summarizes domestic and overseas information on China's IVD market and removes non-industrial data, the size of Chinese IVD market in 2018 exceeded RMB 80 billion (equivalent to more than US$ 11 billion), with around 15% growth year on year.

In 2019, Chinese IVD market exceeded RMB 90 billion (over US$ 12.8 billion), with a growth of about 15%. Among them, imported products account for about 55% in the overall market.

Based on annual reports of 92 diagnostic listed companies (including NEEQ listed companies） in 2018, the total revenue of these 92 listed companies reached RMB 68.21 billion, with 26.87% year-on-year growth; the attributable net profit was RMB 7.87 billion, with year-on-year increase of 16.76% (including operating companies).

2019 annual reports of 82 diagnostic listed companies (including NEEQ listed companies) showed that the total revenue of 82 listed companies was RMB 74.19 billion, with 19.85% year-on-year growth; and the attributable net profit was RMB 8.02 billion yuan, decreasing with 3.38%.

In the first quarter of 2020, the total revenue of 30 main board listed companies was RMB 12.86 billion, increasing 0.22% than the same quarter in last year. In addition, the attributable net profit was RMB 1.93 billion.

According to statistics, the total market value of the 24 in vitro diagnostic industry listed companies listed on the A-share market in 2019 increased by RMB 168.35 billion, with an overall increase of 58%. At the end of 2018, the average static P/E ratio of 24 listed companies in the IVD industry was 45.19 times, while the end of 2019, the average static P/E ratio of 27 listed companies in the IVD industry was 44.01 times.